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Abstract
Background: Around 27,000 new cases of prostate cancer are diagnosed every year in Spain and 5400 die from
this disease. Radiotherapy (RT), alone or combined, has proven to be effective as initial treatment in patients with
localized disease. Our objective was to evaluate the use of external beam RT (EBRT) in our region, comparing the
indication rate and irradiation rate and examining variability in its application among hospitals.
Methods: We conducted a review of RT guidelines and indication studies for prostate cancer (% expected
irradiation). Data were gathered from all twelve public healthcare centers in Andalusia (Spain) on RT-treated
prostate cancer patients during 2013 (% actual irradiation) and from nine of the centers on RT discharge reports.
Information was classified according to type of hospital, tumor risk category and RT treatment (technique, dosage,
volume, toxicity).
Results: The estimated RT rate was 67 % (1289/1917), 43 % were aged > 70 years, 44.7 % had ECOG performance
status of 0); 44.7 % had high-risk tumors; 57 % underwent RT associated with hormone therapy; 70 % of patients
receiving RT were treated with 3D planning (30 % IGRT); and doses were 70–76 Gy in 70 % of cases and >76 Gy in
10.7 %. Acute gastrointestinal and genitourinary toxicities were < grade 2 in 79 and 89 % of patients, respectively.
An irradiation rate significantly below the mean for the study was found in four provinces. There was a significant
difference among provinces in the distribution of risk groups.
Conclusions: Underutilization of EBRT was estimated to be around 30 % in prostate cancer patients, with an
elevated variability in irradiation rates among hospitals related to differences in available technology and in the
distribution of patients with different risk levels. These data should be a matter of concern to regional health
managers, given the negative and measurable impact on the survival of patients.
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Background
Prostate cancer (PrC) is the second most frequent tumor
in males in the industrialized world, with an estimated
standardized rate (European population) of 62.5 × 105
and a mortality of 8.8 × 105 (27,852 and 5481 cases,
respectively). In Andalusia, a region in southern Spain
with 8.4 million inhabitants, PrC represents a total of
3280 new cases/year and 1250 deaths/year [1–3]. An
increase in this disease has been detected over the past
few decades, probably in part due to a greater use of
prostate-specific antigen (PSA) testing, without ruling out
the influence of unknown factors [4].
This higher incidence is associated with an increase in
the number of patients with localized disease (gland and
surrounding anatomical area) at diagnosis, permitting
greater disease control by surgery and radiotherapy (RT).
The classification in risk degrees for localized disease and
prognostic algorithms enable local treatment options to be
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offered with or without hormone therapy, which is cur-
rently the standard treatment [5]. Despite the lack of ran-
domized clinical trials to compare among prostatectomy,
external beam RT (EBRT), or brachytherapy for localized
disease, there is international consensus on the role of
EBRT in the local treatment of PrC, as reflected in the
guidelines of scientific societies [6]. Recent advances have
allowed 3D planning techniques to be used to deliver high
irradiation doses with lower toxicity. EBRT techniques
using guided imaging and modulated dose intensity,
although not available in all RT departments, permit a
superior dose distribution that confers higher treatment
safety with lower toxicity and is expected to achieve
greater control of the disease. It also allows the delivery
of larger doses through hypofractionation, shortening
treatment times. These technological improvements
have led to the application of a variety of RT regimens
for these tumors [7].
Medical practice variability (MPV) can have a negative
impact on health outcomes and cost-effectiveness [8]. MPV
has been attributed to differences in the availability
(number or geographic proximity) of resources and in
the practice of professionals [9]. Previous research in
our setting (VARA II), based on a review of clinical records
and treatment reports and considering recommended indi-
cations, showed that the underutilization of EBRT in lung
cancer had a negative impact on patient outcomes [10–12].
The objectives of the present study were to evaluate
the use of EBRT as initial treatment for patients with
PrC in hospitals in a region of Southern Spain, comparing
expected with actual irradiation rates and examining the
variability in its application among participating centers
and associated factors.
Methods
A longitudinal retrospective study was conducted be-
tween January 1 and December 31 2013 in the 12 public
hospitals with RT facilities in Andalusia, an autonomous
community in southern Spain with 8.4 × 106 inhabitants.
These centers are distributed among the 8 provinces that
form the autonomous community, ensuring coverage of
the whole population.
We gathered data on all patients with non-metastatic
PrC of any histological type and degree of risk whose ini-
tial treatment was EBRT. This information was obtained
from the clinical management computer systems associated
with the RT equipment (Varis®, Lantis®, Impac®, Mosaiq®
networks, etc.). Demographic data were gathered from the
Spanish National Institute of Statistics (http://www.ine.es)
[13], while information on cancer incidence and distribu-
tion among histological types and stages were extrapolated
using data from the 2010 National Prostate Cancer Registry
[14] and Carlos III Health Institute (Madrid) [15]. The
irradiation rate was obtained by calculating the percentage
of irradiated cases with respect to the total number of di-
agnosed cases, examining the variability by hospital/catch-
ment area. Expected irradiation rates were based on the
studies by Tyldesley S et al. and Delaney et al. [16, 17],
which define the proportion of patients at each risk level
for whom RT (external beam or brachytherapy) would be
indicated. Data were gathered from the clinical records on
the general state of patients as measured with the ECOG
Performance Status (PS) score.
Acute toxicity data were measured following the
EORTC/RTOG criteria.
EBRT application variability was studied by analyzing
the cases treated in nine of the participating centers,
gathering data on the characteristics of the hospital
(treatment units/professionals), patients, therapies, and
tumors (histology, stage) and on the RT modalities and
regimens (doses and combination with hormone therapy
[HT]) (Table 1). We excluded patients treated after sur-
gery or after biochemical recurrence and those receiving
palliative treatment for bone metastases. Information on
each patient was extracted from treatment discharge
reports by trained personnel under the supervision of
the research team.
Ethical approval
The study has been approved by the provincial Biomed-
ical Research Ethics Committee and has therefore been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. All patients
gave their informed consent prior to their inclusion in
the study. Details that might disclose the identity of the
subjects under study have been omitted.
Statistical analysis
A descriptive analysis was performed, calculating central
tendency and dispersion statistics (mean, median, inter-
quartile range, standard deviation, 95 % confidence
interval). The chi-square (χ2) test was used to compare
qualitative variables and exact Fisher’s test for binary
variables. Relationships among quantitative variables were
studied by using Pearson’s correlation coefficient (or the
non-parametric Kendall’s Tau-b and Spearman tests) and
linear regression analysis. A two-sided p < 0.05 was
considered significant. SPSS version 12.0 was used for
statistical analyses.
Table 1 Study variables
Tumor Histology, classification (low, intermediate, and
high risk), diagnosis date, and Performance Score
RT treatment Dates of start and end of RT, volume, total dose,
dose fraction, technique, energy, acute toxicity,
interruptions and cause, associated hormone
therapy: duration and drugs.
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Results
Irradiation rate
Among patients with PrC, 88 % are expected to have lo-
calized disease at their diagnosis, estimating an optimal
irradiation rate of 58 % with EBRT and 9 % with brachy-
therapy [18]. Accordingly, 1917 of the present series of
PrC patients would be expected to undergo RT, 41 % of
low-risk (n = 1183), 25 % of intermediate-risk (721), and
31 % of high-risk (n = 894) patients. In fact, only 1160 of
the patients received EBRT and 129 brachytherapy, i.e.,
67 % of the expected total.
EBRT type and variability
As shown in Table 2, the type of EBRT treatment was
recorded in 609 (52.50 %) of the 1160 irradiated patients;
43 % were aged > 70 years; 47.6 % were in a good general
state (PS = 0); 44.7 % had high-risk, 32 % intermediate-
risk, and 23 % low-risk disease. 57 % received RT com-
bined with HT;67 % of patients received a combined
RT-HT therapy (we are excluding patients with BQT
(14.4 %). On the other hand, the percentage of patients re-
ceiving a combined RT-HT stratified by risk group was as
follows: 23 % for low-risk patients, 71.5 % for intermediate-
risk patients, and 89.5 % for high-risk patients. Excluding
those patients treated with BQT as monotherapy, 72.5 % of
patients were irradiated using 3D planning techniques;
70.7 % received 76 Gy (1.8–2 Gy/fr) and 10.8 % were pre-
scribed higher doses than 76 Gy (1.8–2Gy/fr). 18.5 % re-
ceived less than 76 Gy but using a hypo-fractionation
scheme with doses-per-fraction > 2 Gy. Volumes were cen-
tered on prostate gland in 64 % and seminal vesicles in
23 %. Only 12.9 % received RT to the lymph nodes; this
might be explained by the fact that 46.3 % of patients were
both high-risk and aged 70 years or more, indicating clini-
cians reluctance and true concern to prescribed lymph
nodes RT in patients identified as frail, elderly patients, in
order to avoid a live-threatening toxicity. Acute intestinal
and genitourinary toxicities were < grade 2 in 79 and 89 %
of patients, respectively.
Irradiation dosages and volumes were significantly corre-
lated with risk levels (Table 3). A high risk was associated
with doses >76 Gy (p < 0.003) and with the inclusion of ves-
icles and lymph nodes in the target volume (p < 0.001).
However, neither intestinal nor urinary toxicity was corre-
lated with the total dose, treated volume, or degree of risk.
The participating hospital centers showed significant
differences in the irradiation rate. As shown in Table 4, a
significantly lower number of patients underwent RT
than expected in hospitals 3, 6, 7, and 8, whereas a sig-
nificantly higher number than expected was treated in
hospital 4 (Table 4). There was also a difference in the
distribution of risk groups (Fig. 1), with a significantly
higher proportion of high-risk patients in hospitals 5
and 6 than in the others. Concerning the analysis of
Table 2 Main variables characteristics
Age (ranges) 40–60 77 (12.6 %)
61–70 262 (43 %)
>70 265 (43.5 %)
Unknown 5 (0.8 %)
Performance score 0 290 (47.6 %)
1 72 (11.8 %)
2 1 (0.2 %)
3 1 (0.2 %)
Unknown 245 (40.2 %)
Risk (D’Amico) Low 140 (23 %)
Intermediate 195 (32 %)
High 272 (44.7 %)
Unknown 2 (0.3 %)
Treatment RT 85 (14 %)
RT + HT 348 (57.1 %)
Cx + RT 87 (14.3 %)
BQ 88 (14.4 %)
Unknown 1 (0.2 %)
RT technique 3D 369 (60.6 %)
IGRT 140 (23.0 %)
BQ 88 (14.4 %)
Unknown 12 (2.0 %)
RT dose (Gy) <76 96 (15.8 %)
76 367 (60.3 %)
>76 56 (9.2 %)
Unknown 2 (0.3 %)
BQ 88 (14.4 %)
Volumea Prostate 331 (63.5 %)
+ Vesicles 119 (22.8 %)
+ Lymph nodes 67 (12.9 %)
Unknown 4 (0.8 %)
Toxicityb GI 0 218 (41.8 %)
1 175 (33.6 %)
2 86 (16.5 %)
3 2 (0.4 %)
Unknown 40 (7.7 %)
GU 0 432 (82.9 %)
1 38 (7.3 %)
2 14 (2.7 %)
3 1 (0.2 %)
Unknown 36 (6.9 %)
RT radiotherapy, HT hormone therapy, Cx surgery, IGRT image-guided radiation
therapy, GI gastrointestinal, GU genitourinary
aTreatment volume excluding Brachytherapy
bToxicity excluding Brachytherapy
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other variables, such as total dose, dose per fraction and
technique, some differences between hospitals were found.
Regarding total dose most centers prescribed 76 Gy in
70–90 % of cases. Only in hospital 6 and 7 was a total
dose < 76 Gy prescribed, but using an hypofractionated
scheme with doses per fraction > 2Gy; it should be pointed
out that these hospitals had at their disposal IGRT sys-
tems. Hospital 3 was the one who presented the highest
percentage of patients treated with total doses > 76 Gy. Re-
garding the techniques used in each center, hospital 1, 2
and 3 lacked any IGRT system. Hospital 1, 3 and 5 did not
have BQT and the percentage of patients being treated
with this technique (referring patients to other centers)
was lower than the rest of centers.
Discussion
Knowledge of irradiation rates defines the contribution
of radiation oncologist to the management of cancer pa-
tients and is important for the allocation of RT resources
[19, 20]. Various methods have been proposed to estimate
the irradiation rate as accurately as possible, following
benchmarking [21], expert, or evidence-based criteria [22].
The most updated approach [18] was used in this study
of hospitals in a southern Spanish region, which found
that EBRT was not administered to almost three out
of every ten patients who could have been expected to
receive it.
There are various possible explanations for this apparent
underutilization of RT. Urologists, who initiate the PrC
diagnostic process, may be more inclined to support
surgery rather than EBRT, especially in low- and
intermediate-risk patients, who represented a large
proportion of the present series. Thus it would be im-
portant to develop multidisciplinary teams, in order to
better assign patients who might benefit from a RT
treatment. We highlight the finding that image-guided
RT, considered the most effective technique [23], was
only possible in 30 % of the patients, concentrated in
the three centers possessing this facility at the time of
the study. Despite efforts to improve the situation over
the past few years, the availability of this technology
remains suboptimal in Andalusia [3, 24]. Technological
limitations may also account for the low total dosages
and little utilization of doses > 2 Gy per fraction (hypo-
fractionation), a widespread approach in PrC treatment,
although it may also reflect certain reservations among
professionals about the application and safety of less
standard techniques [11]. The low dosages may in part
explain the low toxicity levels, but further research is
required to establish their effect on final patient outcomes
and compare these with other reports [25]. Another
technological limitation in Andalusia was that only 4
centers were able to offer a brachytherapy treatment to
patients having a low-risk which, as it is already well
established in the literature, is an alternative to other
Table 3 Relationship of risk with variables
Variables Pearson’s Chi2 test P Comment
Risk– total dose 15.738 0.003 Higher risk, higher dose
Risk – dose fraction 30.746 0.000
Risk – volume 121.225 0.000 Higher risk, higher volume
Risk – urinary toxicity 8.602 0.197 No relationship
Risk –gastrointestinal toxicity 3.608 0.730 No relationship














low high low high
3 518 687 103 1.99 1.60 2.37 83 1.60 1.26 1.94
11 698 601 130 1.86 1.54 2.18 108 1.55 1.25 1.84
8a 700 570 139 1.98 1.65 2.31 90 1.28 1.02 1.55
6a 798 580 158 1.98 1.67 2.29 258 3.23 2.84 3.63
2,7 918 382 182 1.98 1.69 2.27 185 2.01 1.72 2.31
4,5a 1 238 291 246 1.99 1.74 2.24 44 0.36 0.25 0.46
1,10a 1 619 497 321 1.98 1.77 2.20 211 1.30 1.13 1.48
9a 1 940 027 385 1.98 1.79 2.18 300 1.55 1.37 1.72
aSignificant differences between observed and expected values
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treatments [26]. Another important issue in terms of
variability would be the importance of active vigilance
in a subset of patients with low-risk; even if this active
surveillance is a recommended option [27] for this
group of patients, especially the older one among them,
in Andalusia is not still an option currently offered to
our patients. At least, authors of this article have no
record of it.
Besides differences in equipment, the elevated variabil-
ity among hospitals would also be related to variations
in the distribution of patients with different risk levels.
Thus, hospitals 5 and 6 had a much larger percentage of
high-risk patients, which would imply a more frequent
use of surgery as local treatment.
Besides all of these causes mentioned above, we have
to conclude that an important part of the variability
found within Andalusia is due to an intrinsic variability
between physicians.
Study limitations include the lack of data on treatment
regimens from three hospitals and the non-participation
of private centers, although these only represent around
i5–10 % of PrC patients in our region. However, rele-
vant nformation was obtained on the inadequacy and
variability of RT utilization, making the case for a
greater prioritization of scarce resources to remedy this
situation [28].
Given the impediments to conducting clinical trials on
RT, further research is warranted to compare its utilization
and outcomes in different cancer types among centers
with varied technological resources [29, 30].
Conclusions
In representative public hospitals from our region, radio-
therapy was not delivered to around 30 % of prostate
cancer patients who could benefit from this treatment.
An elevated variability among centers in the irradiation
rate was related to differences in risk distribution and
the availability of high-performance radiation therapy.
These data should be a matter of concern to regional
health authorities, given the measurable negative impact
on the survival of patients.
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